CollPlant Biotechnologies Ltd.
CLGN
$2.35
-$0.07-2.89%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 3,565.22% | 1,845.19% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | 3,565.22% | 1,845.19% | |
| Cost of Revenue | -- | -- | 397.75% | 44.47% | |
| Gross Profit | -- | -- | 8,979.21% | 2,917.31% | |
| SG&A Expenses | -- | -- | -11.05% | 15.46% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 6.18% | 8.99% | |
| Operating Income | -- | -- | 56.06% | 54.98% | |
| Income Before Tax | -- | -- | 58.53% | 58.70% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | 58.53% | 58.70% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | 58.53% | 58.70% | |
| EBIT | -- | -- | 56.06% | 54.98% | |
| EBITDA | -- | -- | 59.99% | 59.43% | |
| EPS Basic | -- | -- | 59.91% | 59.81% | |
| Normalized Basic EPS | -- | -- | 112.48% | 116.14% | |
| EPS Diluted | -- | -- | 58.94% | 58.81% | |
| Normalized Diluted EPS | -- | -- | 110.23% | 113.62% | |
| Average Basic Shares Outstanding | -- | -- | 3.19% | 3.60% | |
| Average Diluted Shares Outstanding | -- | -- | 4.11% | 4.54% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |